• Ceryx’s Cysoni pacing technology is designed to provide superior therapeutic outcomes for Heart Failure patients by improving cardiac output using Respiratory Sinus Arrythmia (RSA) inputs to inform the pacing algorithm.
• RSA is the natural synchronisation of the heart and lungs that maximises cardiac efficiency and output, RSA is frequently absent in Heart Failure patients.
• Ceryx’s Cysoni pacing technology has been proven to increase cardiac output by up to 20%, reduce symptoms of heart failure such as apnoeas and reverse myocardial damage in a controlled in-vivo study. It may be used alongside existing therapies.

Ceryx today announced that the first patient has been enrolled in the RSA-Pace multi-center study at Waikato Hospital in Hamilton, New Zealand. The study is designed to evaluate the safety of the Cysoni temporary pacing technology in the treatment of post-surgical heart failure patients that require temporary pacing. The RSA-Pace study will enroll up to 60 patients at centers in the UK, New Zealand and Australia.

“We are delighted to have enrolled the first patient in this important study. The Ceryx Cysoni pre-clinical results have been most impressive and have shown that this technology has the potential to improve cardiac output compared to existing pacing technologies. This is an exciting and novel approach, and we are interested to understand the benefits of RSA pacing in a post-surgical patient population” said Dr Martin Stiles, Principle Investigator at Waikato Hospital.

“We would like to thank Dr Stiles and the team at Waikato” said Dr Stuart Plant CEO, Ceryx. “We believe that the results from this first in human study will help us understand the role of RSA pacing as we strive to develop temporary and permanent pacing devices based on this unique technology. We are exceptionally pleased with the performance of the Cysoni system so far, it’s ability to restore RSA appears to be exceeding our expectations.”

About Ceryx Medical Ltd:

Ceryx Medical was founded in 2016 and is based in Cardiff, Wales. The company specialises in developing bioelectronic devices that emulate the body’s natural processes to treat chronic conditions such as heart failure. By focusing on restoring the natural synchronisation between the heart and lungs, known as Respiratory Sinus Arrhythmia (RSA), Ceryx Medical aims to enhance cardiac function and improve patient outcomes.

The company is supported by investors including the Development Bank of Wales, Parkwalk Advisors, BGF, Icehouse Ventures, Maven, and various angel investors.

For more information please visit: https://www.ceryxmedical.com/

About Heart Failure:

It is estimated that Heart Failure affects at least 64 million people worldwide. Heart failure is a long-term condition where the heart cannot pump blood around the body properly. It can be caused by various problems, such as coronary heart disease, high blood pressure or heart valve damage.  Increasing cardiac output may improve or alleviate symptoms of Heart Failure.

About Cysoni™:

Cysoni a bionic pacing technology that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘Respiratory Sinus Arrhythmia’ (RSA). Cysoni replicates this natural interaction, triggering heartbeats based on respiratory function, as opposed to ‘metronomic’ generation by traditional pacemakers. This potential advantage of Cysoni allows breath-by-breath induced variation in the inter-beat interval. In essence, Cysoni listens and responds to the cardiorespiratory system and optimises its performance.